CAR T Cells: Second-Line Treatment Option for NHL? - NCI
4.7 (775) · $ 22.99 · In stock
Recent trial results suggest that CAR T cells may be superior to standard treatments for B-cell NHL that has not responded or has returned after treatment.
Chimeric antigen receptor T-cell therapies for lymphoma
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B- cell lymphomas
Cancers, Free Full-Text
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL - ScienceDirect
CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma, Experimental Hematology & Oncology
Prospects in the management of patients with follicular lymphoma beyond first-line therapy
Fertility and CAR T-cells: Current practice and future directions - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Frontiers Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies
